The IL-6 / JAK / Stat 3 Feed-Forward Loop Drives Tumorigenesis and Metastasis 1 , 2
暂无分享,去创建一个
K. Manova | E. Stanchina | L. Norton | G. Altan-Bonnet | J. Bromberg | R. Kaplan | D. Lyden | D. Santini | M. Bonafè | S. Gao | Xinmin Zhang | D. Huszar | Marjan Berishaj | C. Ceccarelli | N. Nishimoto | M. Taffurelli | L. Daly | P. Sansone | T. Theilen | J. Cotari | M. Alpaugh | Ming Li | Q. Chang | E. Bournazou | J. Wels | S. Granitto | M. Berishaj
[1] T. Putoczki,et al. Stat3: Linking inflammation to (gastrointestinal) tumourigenesis , 2012, Clinical and experimental pharmacology & physiology.
[2] G. Prendergast,et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. , 2012, Cancer discovery.
[3] R. Figlin,et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. , 2012, Cancer cell.
[4] D. Gabrilovich,et al. Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.
[5] G. Dranoff,et al. Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.
[6] E. Galun,et al. Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis , 2012, Clinical and Translational Oncology.
[7] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[8] W. Gerald,et al. Stat3 Mediates Expression of Autotaxin in Breast Cancer , 2011, PloS one.
[9] R. Figlin,et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. , 2011, Cancer research.
[10] D. Levy,et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. , 2011, Cancer research.
[11] S. Dave,et al. HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. , 2011, Cancer research.
[12] Mithat Gönen,et al. The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.
[13] M. Wicha,et al. Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory Roots , 2011, Clinical Cancer Research.
[14] Hua Yu,et al. Stat3-induced S1PR1 expression is critical for persistent Stat3 activation in tumors , 2010, Nature Medicine.
[15] Sun Park,et al. STAT3 transcriptional factor activated by reactive oxygen species induces IL6 in starvation-induced autophagy of cancer cells , 2010, Autophagy.
[16] R. Figlin,et al. Microenvironment and Immunology Targeting Stat3 in the Myeloid Compartment Drastically Improves the in Vivo Antitumor Functions of Adoptively Transferred T Cells , 2022 .
[17] P. Musiani,et al. Stat3 is required for anchorage‐independent growth and metastasis but not for mammary tumor development downstream of the ErbB‐2 oncogene , 2009, Molecular carcinogenesis.
[18] Hua Yu,et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.
[19] Hua Yu,et al. STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.
[20] Hua Yu,et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.
[21] D. Levy,et al. Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. , 2009, Cancer research.
[22] F. Vesuna,et al. Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells , 2009, Oncogene.
[23] A. Richardson,et al. Reciprocal Effects of STAT5 and STAT3 in Breast Cancer , 2009, Molecular Cancer Research.
[24] J. Pollard,et al. Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.
[25] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[26] Hua Yu,et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. , 2008, The Journal of clinical investigation.
[27] K. Hunter,et al. Mouse Modifier Genes in Mammary Tumorigenesis and Metastasis , 2008, Journal of Mammary Gland Biology and Neoplasia.
[28] Z. Werb,et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. , 2008, Cancer cell.
[29] W. Gerald,et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.
[30] D. Santini,et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. , 2007, The Journal of clinical investigation.
[31] W. Gerald,et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer , 2007, Breast Cancer Research.
[32] Hua Yu,et al. Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.
[33] M. Colombo,et al. The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.
[34] R. Kaplan,et al. Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond , 2007, Cancer and Metastasis Reviews.
[35] S. Rafii,et al. Preparing the "soil": the premetastatic niche. , 2006, Cancer research.
[36] Hua Yu,et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.
[37] Andy J. Minn,et al. Genes that mediate breast cancer metastasis to lung , 2005, Nature.
[38] Goberdhan P Dimri,et al. Mammary epithelial cell transformation: insights from cell culture and mouse models , 2005, Breast Cancer Research.
[39] R. Arlinghaus,et al. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. , 2005, Cancer research.
[40] P. Sinha,et al. Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1 , 2005, The Journal of Immunology.
[41] J. Gregg,et al. Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior , 2005, Clinical & Experimental Metastasis.
[42] Hua Yu,et al. The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.
[43] T. Kishimoto,et al. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody , 2004, Springer Seminars in Immunopathology.
[44] Jeffrey W Pollard,et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.
[45] D. Gabrilovich,et al. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species , 2003, Journal of leukocyte biology.
[46] David L Rimm,et al. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] Nicholas R. English,et al. Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.
[48] S. Barsky,et al. A novel human xenograft model of inflammatory breast cancer. , 1999, Cancer research.
[49] S G Hilsenbeck,et al. Significance of axillary lymph node metastasis in primary breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] F. Miller,et al. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. , 1992, Cancer research.